EYPT EyePoint Pharmaceuticals, Inc. Insider Trading

CEO Jay Duker purchased 1,500 shares of EyePoint at $13.15; holds 100.7K shares post-buy.

Jay S. Duker, the President and CEO, purchased 1,500 shares at $13.15, expanding his holdings from 99.2K shares to 100.7K shares. The transaction occurred when the stock was trading -28.6% below its 52-week high of $18.85 and has risen 3.9% over the prior 30 days, though it remains down 20.6% over 90 days. EyePoint faces significant operational headwinds: annual revenue contracted by 27.5% year-over-year to $966.0K in the latest quarter, and the company posted a full-year net loss of $-59.7M. The purchase, modest in size relative to the CEO's existing stake (1.5% increase), occurs in the context of a deteriorating financial profile and substantial loss accumulation.

Chief Medical Officer Ribeiro Ramiro sells entire 42,544-share stake in EYPT for $727,319.46 amid -6.0% revenue decline and $-59.7M annual loss

Ribeiro Ramiro, Chief Medical Officer, liquidated his complete shareholding of 42,544 shares for $727,319.46 on 2026-01-05, leaving him with zero post-transaction holdings. The sale occurs in the context of a company reporting severe financial distress: annual revenue declined 6.0% year-over-year to $966,000.00 in the latest quarter, while net income was $-59,732,000.00 for the most recent full fiscal year. The stock currently trades at $17.37, near the top of its 52-week range of $4.13–$18.85, having appreciated 24.3% over the past 90 days but fallen 2.5% over 30 days. The complete liquidation by a senior medical executive at a historically elevated valuation warrants investor attention to whether this reflects asymmetric information about clinical or operational trajectory.

Director Karen L. Zaderej purchased 10,000 shares at blended average $5.90 across two transactions, raising holdings 37.7% to 36.5K shares

Karen L. Zaderej, a Director at EyePoint Pharmaceuticals, completed 2 purchases totaling 10,000 shares for $59,000.00 at an average price of $5.90 on 2025-05-16 and 2025-05-19, expanding her position by 37.7% from 26,500 to 36.5K shares. The current price of $6.10 is 52.9% below the 52-week high of $12.94, positioning these purchases near recent lows in a stock that has declined 6.7% over 90 days. Zaderej's cross-ticker track record shows a 100.00% 90-day win rate with average 90-day returns of +14.9% across 3 prior open-market buys; her prior purchase at EYPT on 2024-08-19 also achieved a +14.9% 90-day return, demonstrating consistent timing execution at this ticker specifically. The company is unprofitable with a net income of $-45.2M on quarterly revenue of $24.5M, yet the director's continued accumulation at reduced prices after a 52-week decline suggests conviction despite current fundamentals.

Director Karen L. Zaderej bought 10,000 shares at blended avg $5.44 across 2 purchases; holds now 26.5K shares, +60.6% vs pre-transaction.

Director Karen L. Zaderej purchased a total of 10,000 shares (10.0K shares) for $54,450.00 across 2 separate transactions on May 14-15, 2025, at prices of $5.42 and $5.47, increasing her holdings by 60.6% from 16,500 to 26.5K shares. The company operates at a significant loss—net income of $-45,195,000.00 for the latest full fiscal year—while posting quarterly revenue of $24,453,000.00 with annual revenue growth at -6.0%, indicating operational headwinds. Her prior buy at this ticker on 2024-08-19 delivered positive returns at both 30-day (+11.6%) and 90-day (+14.9%) intervals, and her cross-ticker track record shows 1 prior buy with a 100.00% 90-day win rate, though the sample remains modest. The current stock price of $5.72 sits at -55.8% from the 52-week high of $12.94, creating a depressed valuation environment where the director elected to substantially increase her stake.

Director Ando Goran buys 5,000 shares of EYPT at $7.95; 3 other insiders also bought within 14 days.

Ando Goran purchased 5,000 shares at $7.95 on 2024-08-21, expanding his holdings from 8,150 to 13,150 shares (+61.3%). This buy-side activity occurs in a cluster context: 3 other insiders also purchased shares within the past 14 days. The company is unprofitable (net income $-30.8M over the latest full fiscal year), though it posted quarterly revenue of $9.5M and annual revenue growth of +11.1%. The stock currently trades at $9.05, down 69.5% from its 52-week high of $29.71 and modestly positive on a 30-day basis (+1.3%). The convergence of multiple insider buys at depressed valuations alongside operational losses and recent momentum erosion warrants investor scrutiny of management's confidence thesis versus the underlying business fundamentals.

Director Zaderej buys 12,500 shares at $7.98 as EYPT stock down -69.5% from 52-week high; cluster of 4 insider buys in 14 days

Director Karen L. Zaderej purchased 12,500 shares at $7.98 on 2024-08-19, tripling her position from 4,000 to 16,500 shares (+312.5% increase). The transaction occurred when the stock was trading 69.5% below its 52-week high of $29.71. Notably, 3 other insiders bought within the same 14-day window, forming a cluster buy pattern. Against this backdrop, the company is unprofitable (net income $-30.8M) despite recent revenue growth of 11.1%, with the most recent quarterly revenue at $9.5M. This synchronized insider purchasing at a significant discount from recent highs, combined with the company's cash burn despite top-line growth, presents a pattern investors should examine carefully given the disconnect between growth narrative and profitability.

Director buys 2,567 shares of EYPT at $7.79 on 2024-08-20; 3 other insiders bought in past 14 days

Director Dicicco purchased 2,567 shares at $7.79, increasing her holdings by 34.7% to 9,967 shares. This purchase is part of a broader cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated confidence. The transaction occurred when the stock was trading 69.5% below its 52-week high of $29.71, though the company has posted negative net income of $-30,826,000.00 over its most recent full fiscal year. The concurrence of multiple insider buys at depressed valuations warrants tracking whether this precedes company-level developments or represents a fundamental reassessment of risk.

Director Nancy Lurker buys 3.2K shares of EYPT at $7.88; stock -74.0% from 52-week high; 2 other insiders also bought in past 14 days

Nancy Lurker, a director at EyePoint Pharmaceuticals, purchased 3,173 shares for $25,003.24 on 2024-08-16, increasing her holdings to 97,635 shares. The purchase occurs as the stock trades at $7.72, representing -74.0% from its 52-week high of $29.71, and follows a steep -32.7% decline over the past 90 days. Notably, a cluster of three insiders—including Lurker—have purchased shares within the past 14 days. The company is unprofitable (net income of $-30.8M in its most recent full fiscal year) with quarterly revenue of $9.5M, though it posted annual revenue growth of +11.1%. The convergent buying pattern across multiple insiders during a period of significant price weakness warrants tracking of insider conviction relative to fundamental deterioration and valuation dynamics.